Smoking and CVD. .what role for the Cardiologist? Dr Sandeep Gupta, MD, FRCP
|
|
- Morris Waters
- 5 years ago
- Views:
Transcription
1 Smoking and CVD.what role for the Cardiologist? Dr Sandeep Gupta, MD, FRCP Consultant Cardiologist Whipps Cross/BartsHealth NHS Trusts Hospitals, London, UK
2 Therapeutic Advances in the Treatment of Cardiovascular Disease % 50% Total Mortality Risk Reduction in Post-MI Patients (%) % 20% 7% 27% 22% 30% 10 5 Thrombolysis PPCI/ 1 4 Antiplatelet 2,5 β-blockers 6 ACEI/ARB Inhibitor 7 11 Statins 12,13 thrombolysis Therapy Class 1. GISSI. Lancet.1986, 1987; 2. ISIS Lancet.1988; AIMS. Lancet.1988, 1990; 4. ASSET. Lancet.1988, 1990; 5. Antiplatelet Trialists Collaboration. BMJ.1994; 6. Yusuf et al. ProgCardiovasc Dis.1985;27: ; 7. SAVE. N Engl J Med.1992; 8. AIRE. Lancet. 1993; 9. GISSI 3. J Am Coll Cardiol.1996; 10. ISIS 4. Lancet.1995; 11. TRACE. N Engl J Med.1995; 12. 4S. Lancet. 1994;13. LIPID. N Engl J Med.1998.
3 Post-MI setting Intervention Risk reduction (%) Event rate (%) Stopping smoking, None % Asp/Clop 25 6 B-Blockers Statins 30 3 ACEI
4 Effects of smoking cessation in secondary prevention Meta analysis of 20 studies (1978 to 2000) - 12,603 smokers with coronary heart disease - Follow-up: 3 to 7 years Sustained quitters Continuing smokers n = 5,659 n = 6,944 1,044 deaths 1,884 deaths 18.4% 27.1% RR = 0.64 (CI 95%, ) Deaths - 36% Non fatal myocardial reinfarction: - 32% RR = 0.68 (CI 95%, ) Critchley JA, Capewell S JAMA 2003: 290: 86-97
5 May 2004
6 65% of the world s smokers live in 10 countries
7 The young
8 Tobacco Is a Risk Factor for 6 of the World s 8 Leading Causes of Death Hatched areas indicate proportions of deaths related to tobacco use.
9
10
11 SMOKING: EFFECT ON CORONARY ARTERY DISEASE 1 Progression of existing lesions after 2 years 57% Formation of new lesions after 2 years 50 p= p=0.007 Patients (%) % Patients (%) % 36% Non-smokers Current smokers 0 Non-smokers Current smokers 1. Waters D et al. Circulation 1996;94:614 21
12 Effects of smoking cessation in secondary prevention After CABG Risk of reoperation x 2.5 at 1 year for non quitters 1 After angioplasty Risk of mortality x 1.4 at 4.5 years for non quitters 2 1. Voors AA et al Circulation 1996; 93: Hasdai D et al N Engl J Med 1997; 336:
13 Smoking: a particular risk factor The essential and often unique risk factor for acute coronary syndromes in young adults 6,448 patients with STEMI The prevalence of smoking is very important in myocardial infarction under 50 years.with the same prevalence among men and women % of smokers by age and gender Global Female/Male prevalence = 0.38 Thomas D et al. Étude ALLIANCE Journées Européennes de la SFC Janvier 2007
14 Worldwide burden of disease from exposure to second-hand smoke: a retrospective analysis of data from 192 countries Second-hand smoke = 603,000 deaths worldwide Nearly 2/3 of these deaths are caused by ischaemic heart disease in adult non-smokers Lower respiratory infections in children <5 years Otitis media in children <3 years Asthma in children <15 years Asthma in adults Lung cancer in adults Ischaemic heart disease in adults TOTAL 165, ,150 35,800 21, , ,000 Öberg M et al. Lancet, 2011, 377,
15 For every one cigarette smoked you will lose 11 minutes of life
16 Q: How many cigarettes needed to cause a heart attack?
17 10 th Dec 2010
18 Q: How quickly does a cigarette cause harm?
19
20 Q: How does a cigarette cause harm?
21
22 Q: How long does it take to quit smoking?
23 25 th January 2011
24 Q: What CV benefits with smoking cessation?
25 CARDIOVASCULAR BENEFITS OF SMOKING CESSATION Short-term benefits HDL; decreased LDL Arterial pressure Heart rate Improved arterial compliance Risk of arrhythmic death after myocardial infarction (MI) Platelet volume Long-term benefits reduced risk of: Stroke Recurrent coronary events after MI Arrhythmic death after MI Secondary cardiovascular disease (CVD) events 1. Terres et al. Am J Med 1994; 97: Wannamethee et al. JAMA 1995; 274: Nilsson et al. J Int Med 1996; 240: Oren et al. Angiology 2006; 57: Peters et al. J Am Coll Cardiol 1995; 26: Rea et al. Ann Intern Med 2002; 137: Twardella et al. Eur Heart J 2004; 25:
26
27 The cycle of nicotine addiction Nicotine binding causes an increase in release of Dopamine 1,2 Dopamine gives feelings of pleasure and calmness 1 The smoker craves Nicotine to Nicotine release more Dopamine to restore pleasure and calmness 1 Competitive binding of Nicotine to nicotinic acetylcholinergic receptors causes prolonged activation, desensitization, and upregulation 2 As Nicotine levels decrease, receptors revert to an open state causing hyperexcitability leading to cravings 1,2 Dopamine 1. Jarvis MJ. BMJ. 2004; 328: Picciotto MR, et al. Nicotine and Tob Res. 1999: Suppl 2:S121-S125.
28 Partial Antagonist 1,4 Because CHAMPIX is bound to the receptor, it prevents the binding of nicotine 1. Hays JT et al. Am J Med 2008;121(4A):S32-S42 4. Foulds J. Int J Clin Pract. 2006; 60(5): CHAMPIX reduces the pleasurable and reinforcing effects of smoking
29 Q: Is smoking cessation safe to use in Cardiac patients?
30 January 2010 January 2010
31 Cardiovascular events and all deaths Varenicline (n = 353) Placebo (n = 350) n % n % Any adjudicated cardiovascular event* Coronary artery disease Non-fatal MI Need for coronary revascularization Hospitalization for angina pectoris No different to placebo Hospitalization for congestive heart failure Cerebrovascular disease Non fatal stroke Transient ischemic attack Peripheral vascular disease (PVD) New diagnosis or admission for a procedure to treat PVD Death all causes Cardiovascular death Non cardiovascular death *Reported or observed cardiovascular events or deaths from any cause were reviewed separately and adjudicated under blinded conditions by an independent event committee
32
33
34
35 SMOKING REDUCES BENEFITS ASSOCIATED WITH ANTIHYPERTENSIVE TREATMENT Hypertensive smokers have higher cardiovascular risk despite treatment for blood pressure Journath G et al. Blood Pressure 2005;14:144 50
36 SMOKING REDUCES SOME OF THE BENEFITS OF STATINS Up to a 63% higher risk of vascular events in smokers vs nonsmokers despite treatment with statins Statin Milionis HJ et al. Angiology 2001;52:575 87
37
38 Evidence from the UK Real Price and Consumption of Cigarettes in the UK, CONSUMPTION Price ( ) 1994 value PRICE Source: Townsend J 1998, Central Statistical Office (UK) ( ) Year 1.25
39 Cost effectiveness
40 A Brief Intervention (?) Ask about smoking status Advise to quit Assess willingness to quit Assist by offering treatment Arrange follow up Fiore MC, et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. US Department of Health and Human Services. Public Health Service; May Available at:
41 ABC is a reminder of what to do A = Ask about smoking B = Brief advice to be smokefree C = Cessation support Ministry of Health New Zealand Smoking Cessation Guidelines. Wellington: Ministry of Health.
42 Advising to quit versus offer of treatment 70 % increase in quit attempts Advice Offer of treatment 42 Aveyard P. Keeping smoking cessation interventions brief and effective. Smoking Cessation Rounds 2009; Vol 3, Issue 2.
43 Potential algorithm for smoking in the cardiac setting Step 1: ASK 1 On admission to A&E or CCU, ASK if patient is a smoker and RECORD it if they are This can be done by any member of the multi-disciplinary team Smoker: No Smoker: Yes Suggestion: Use self adhesive coloured labels on the notes or patient chart to identify smoking status Step 2: ADVISE 2 When the patient s condition has been stabilised, ADVISE the patient that they should stop smoking in order to reduce their risk of further CV complications. Ask if they are willing to try to stop. Willing: No Willing: Yes Step 3: REFER and/or TREAT Ask that they think about the benefits of stopping and that they ask for help if they want to try in the future 3 Reinforce their decision and give the patient some reading material on the benefits of stopping smoking REFER the patient to a specialised clinic for smoking cessation support and/or, if appropriate, supply an initial prescription Clinic in same hospital: No Clinic in same hospital : Yes Ask the clinic staff to visit the patient while they are in hospital Write to the patient s GP regarding their smoking status and actions that have been taken. Request GP follow up. Ministry of Health New Zealand Smoking Cessation Guidelines. Wellington: Ministry of Health
44 What about electronic cigarettes? A solution that could lead to the end of tobacco? Or A huge gamble that will harm health and lead young people to smoking? Better Lung Health For All
45 Will e-cigarettes encourage children to start smoking? Most UK children have heard of e-cigarettes In one 2015 survey by ASH: 13% of year olds had tried them at least once 2.4% had used them regularly (once a month or more) Better Lung Health For All Source: ASH (2015)
46 What are the benefits of e-cigarettes? Better Lung Health For All
47 What are the benefits of e-cigarettes? Less harmful than conventional cigarettes Far fewer harmful components Better Lung Health For All
48 Are e-cigarettes safe? Image: Mikael Häggström, from Wikipedia Better Lung Health For All
49 Mechanisms by which nicotine may contribute to Coronary Heart Disease Hyperlipididemia Benowitz, 1991 Endothelial Injury Premature Atherosclerosis NICOTINE Platelet Activation Thrombosis Sympathoadrenal Activation Coronary Vasoconstriction Increased Heart Rate Myocardial Contractility Hemodynamic Stress T X A 2 Vascular Stenosis or Occlusion CARBON MONOXIDE Decreased Oxygen Transport MECHANISMS Possible Increased Circulating Catecholamines Myocardial Ischemia or Infarction Probable Definite Arrhythmias Sudden Death Benowitz, 1991
50
51 Referrals to stop smoking service
52 Brief advice works You advise just one smoker every day to quit (time taken = 30 seconds) Over 40 days this would have taken up 20 minutes of your time, but one of those 40 people will quit long term* Over 1 year and you will have prompted six people to stop smoking, using about 2 hours effort from you Consider that by investing 2 hours of your time in that year, you ve saved 3 of those people s lives! *Lancaster T & Stead L. (2004) Physician advice for smoking cessation, Cochrane Database Syst Rev, CD000165
Smoking Cessation: Good News at Last!
Smoking Cessation: Good News at Last! Andrew L. Pipe, CM, MD The Minto Prevention & Rehabilitation Centre University of Ottawa Heart Institute Ottawa, Ontario. Canada apipe@ottawaheart.ca Declaration of
More informationSMOKING CESSATION WORKSHOP. Dr Mark Palayew December
SMOKING CESSATION WORKSHOP Dr Mark Palayew December 5 2016 Conflicts of Interest None Case 1 Mr. T is a 55 year old smoker 2 packs/day He has been smoking continuously since age 16 When he wakes up at
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationAntiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.
Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.Κιλκίς Primary CVD Prevention A co-ordinated set of actions,
More informationShould All Patients Be Treated with Ace-inh /ARB after STEMI with Preserved LV Function?
Should All Patients Be Treated with Ace-inh /ARB after STEMI with Preserved LV Function? Avi Shimony, MD, FESC Cardiology Division Soroka University Medical Center Ben-Gurion University, Beer-Sheva Disclosure
More informationDisclosures. Speaker s bureau: Research grant: Advisory Board: Servier International, Bayer, Merck Serono, Novartis, Boehringer Ingelheim, Lupin
Disclosures Speaker s bureau: Research grant: Advisory Board: Servier International, Bayer, Merck Serono, Novartis, Boehringer Ingelheim, Lupin Servier International, Boehringer Ingelheim Servier International,
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationBalancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients
SYP.CLO-A.16.07.01 Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients dr. Hariadi Hariawan, Sp.PD, Sp.JP (K) TOPICS Efficacy Safety Consideration from Currently Available Antiplatelet Agents
More information03/30/2016 DISCLOSURES TO OPERATE OR NOT THAT IS THE QUESTION CAROTID INTERVENTION IS INDICATED FOR ASYMPTOMATIC CAROTID OCCLUSIVE DISEASE
CAROTID INTERVENTION IS INDICATED FOR ASYMPTOMATIC CAROTID OCCLUSIVE DISEASE Elizabeth L. Detschelt, M.D. Allegheny Health Network Vascular and Endovascular Symposium April 2, 2016 DISCLOSURES I have no
More information9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?
Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial
More informationSESSION 3 11 AM 12:30 PM
SESSION 3 11 AM 12:30 PM for the Primary Prevention of Cardiovascular Disease: A Personalized Approach SPEAKER Samia Mora MD, MHS Presenter Disclosure Information The following relationships exist related
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationHEALTH TARGETS IN PRIMARY CARE
HEALTH TARGETS IN PRIMARY CARE MORE HEART AND DIABETES CHECKS BETTER HELP FOR SMOKERS TO QUIT Better Help for Smokers to Quit 90% of enrolled patients who smoke and are seen by General Practice, will be
More informationPerformance Measure Name: TOB-3 Tobacco Use Treatment Provided or Offered at Discharge TOB-3a Tobacco Use Treatment at Discharge
Measure Information Form Collected For: The Joint Commission Only CMS Informational Only Measure Set: Tobacco Treatment (TOB) Set Measure ID #: Last Updated: New Measure Version 4.0 Performance Measure
More informationRikshospitalet, University of Oslo
Rikshospitalet, University of Oslo Preventing heart failure by preventing coronary artery disease progression European Society of Cardiology Dyslipidemia 29.08.2010 Objectives The trends in cardiovascular
More informationEvidenceNOW SW Learning Collaborative. Kyle Knierim, MD January 2017
EvidenceNOW SW Learning Collaborative Kyle Knierim, MD January 2017 What is cardiovascular disease? Why are we even talking about cardiovascular disease? What can we do to prevent and treat cardiovascular
More information2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension.
2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension Writing Group: Background Hypertension worldwide causes 7.1 million premature
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationPerformance Measure Name: Tobacco Use: Assessing Status after Discharge
Measure Information Form Collected For: The Joint Commission Only CMS Informational Only Measure Set: Tobacco Treatment (TO) Set Measure ID #: Last Updated: New Measure Version 4.0 Performance Measure
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu Indicator area: Pulse rhythm assessment for AF Indicator: NM146 Date: June 2017 Introduction There is evidence
More informationElectronic Cigarettes, Nicotine and Policy Implications
Electronic Cigarettes, Nicotine and Policy Implications Neal L Benowitz MD University of California San Francisco The E-Cigarette Summit The Royal Society London November 17, 2016 Disclosures Dr Benowitz
More informationA multicenter tobacco cessation program in acute coronary syndrome
A multicenter tobacco cessation program in acute coronary syndrome PD Nicolas Rodondi, MD, MAS Research Fellow: Reto Auer, MD Head of the Cardiovascular Prevention & Lipid Clinic Department of Ambulatory
More informationwell-targeted primary prevention of cardiovascular disease: an underused high-value intervention?
well-targeted primary prevention of cardiovascular disease: an underused high-value intervention? Rod Jackson University of Auckland, New Zealand October 2015 Lancet 1999; 353: 1547-57 Findings: Contribution
More informationCoronary heart disease and stroke
4 Coronary heart disease and stroke Overview of cardiovascular disease Cardiovascular disease (CVD), also called circulatory disease, describes a group of diseases which are caused by blockage or rupture
More informationA spotlight on becoming Smokefree NHS and local implementation
A spotlight on becoming Smokefree NHS and local implementation James Mapstone Deputy Regional Director, South of England Public Health England Jennie Leleux Health & Wellbeing Programme Manager, Public
More informationThe TNT Trial Is It Time to Shift Our Goals in Clinical
The TNT Trial Is It Time to Shift Our Goals in Clinical Angioplasty Summit Luncheon Symposium Korea Assoc Prof David Colquhoun 29 April 2005 University of Queensland, Wesley Hospital, Brisbane, Australia
More informationThe Impact of Smoking on Acute Ischemic Stroke
Smoking The Impact of Smoking on Acute Ischemic Stroke Wei-Chieh Weng, M.D. Department of Neurology, Chang-Gung Memorial Hospital, Kee-Lung, Taiwan Smoking related mortality Atherosclerotic vascular disease
More informationPreventive Cardiology Scientific evidence
Preventive Cardiology Scientific evidence Professor David A Wood Garfield Weston Professor of Cardiovascular Medicine International Centre for Circulatory Health Imperial College London Primary prevention
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Primary prevention of CVD Potential output:
More informationSafety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD
Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD Mun K. Hong, MD Associate Professor of Medicine Director, Cardiovascular Intervention and Research Weill Cornell
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationShould we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway
Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway The Polypill A strategy to reduce cardiovascular disease by
More informationPrimary Care Smoking Cessation. GP and Clinical Director WRPHO Primary Care Advisor MOH Tobacco Team Target Champion Primary Care Tobacco
Primary Care Smoking Cessation Dr John McMenamin GP and Clinical Director WRPHO Primary Care Advisor MOH Tobacco Team Target Champion Primary Care Tobacco Target or Tickbox? The Tobacco health target:
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationProtecting the heart and kidney: implications from the SHARP trial
Cardiology Update, Davos, 2013: Satellite Symposium Protecting the heart and kidney: implications from the SHARP trial Colin Baigent Professor of Epidemiology CTSU, University of Oxford S1 First CTT cycle:
More informationDECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.
DECLARATION OF CONFLICT OF INTEREST Lecture fees: AstraZeneca, Ely Lilly, Merck. Risk of stopping dual therapy. S D Kristensen, FESC Aarhus Denmark Acute coronary syndrome: coronary thrombus Platelets
More informationVarenicline and cardiovascular and neuropsychiatric events: Do Benefits outweigh risks?
Varenicline and cardiovascular and neuropsychiatric events: Do Benefits outweigh risks? Sonal Singh M.D., M.P.H, Johns Hopkins University Presented by: Sonal Singh, MD MPH September 19, 2012 1 CONFLICTS
More informationSmoking Cessation Pilot Program
Smoking Cessation Pilot Program Alyson Bettega Oral Health Therapist alysonb@nrch.com.au Aim of this session Increased awareness of cigarette smoking statistics Improved knowledge of smoking cessation
More informationISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW
ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW 2014 PQRS OPTIONS F MEASURES GROUPS: 2014 PQRS MEASURES IN ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP: #204. Ischemic Vascular Disease (IVD):
More informationMacrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?
Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists
More informationthe high CVD risk smoker
Smoking Cessation: population and patients A comprehensive approach to the smoker the high CVD risk smoker Catriona Jennings Cardiovascular Specialist Research Nurse Imperial College London European Society
More information7 th Munich Vascular Conference
7 th Munich Vascular Conference Secondary prevention of major cardiovascular events in patients with CHD or PAD - What can we learn from EUCLID and COMPASS, evaluating Clopidogrel, Ticagrelor and Univ.-Prof.
More informationStatistical challenges of meta-analyses of randomised clinical trials in a regulatory setting
Statistical challenges of meta-analyses of randomised clinical trials in a regulatory setting Frank Pétavy ISCTM 14th Annual Scientific Meeting, Washington D.C. Presented by Frank Pétavy on 21 February
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Peripheral arterial disease Potential output:
More informationCurrent Advances and Best Practices in Acute STEMI Management A pharmacoinvasive approach
Current Advances and Best Practices in Acute STEMI Management A pharmacoinvasive approach Frans Van de Werf, MD, PhD University Hospitals, Leuven, Belgium Frans Van de Werf: Disclosures Research grants
More informationBecause we care about your health
Contact us For information on Trust services see www.awp.nhs.uk PALS To make a comment, raise a concern or make a complaint, please contact the Trust s Patient Advice and Liaison Service (PALS). Smoking
More informationApproach to Multi Vessel disease with STEMI
Approach to Multi Vessel disease with STEMI MANAGEMENT OF ST-ELEVATION MYOCARDIAL INFARCTION Dr. Thomas Alexander, M.D; D.M; F.A.C.C. Senior Consultant and Interventional Cardiologist Kovai Medical Centre
More informationOptimal medical therapy in patients with stable CAD
Optimal medical therapy in patients with stable CAD Robert Storey Professor of Cardiology, University of Sheffield and Academic Director and Honorary Consultant Cardiologist, Cardiology and Cardiothoracic
More informationDecline in CV-Mortality
Lipids id 2013 What s Changed? Christopher Granger, MD Disclosure Research contracts: AstraZeneca, GSK, Merck, Sanofi- Aventis, BMS, Pfizer, The Medicines Company, Medtronic Foundation, and Boehringer
More informationDisclosures. May 15 th, Influenza Vaccination as Secondary Prevention for Acute Coronary Events Where do we need to go in clinical practice?
Influenza Vaccination as Secondary Prevention for Acute Coronary Events Where do we need to go in clinical practice? May 15 th, 2014 Robi Goswami, MD Cardiologist Piedmont Heart Institute Disclosures None
More informationCORONARY ARTERY DISEASE (CAD) MEASURES GROUP OVERVIEW
CONARY ARTERY DISEASE (CAD) MEASURES GROUP OVERVIEW 2014 PQRS OPTIONS F MEASURES GROUPS: 2014 PQRS MEASURES IN CONARY ARTERY DISEASE (CAD) MEASURES GROUP: #6. Coronary Artery Disease (CAD): Antiplatelet
More informationHow best to get your patients to stop smoking. Dr Alex Bobak GP and GPSI in Smoking Cessation Wandsworth, London
How best to get your patients to stop smoking Dr Alex Bobak GP and GPSI in Smoking Cessation Wandsworth, London 1 2 Smoking can cause at least 14 different types of cancer 3 Smokers want to stop All smokers
More informationChest pain and troponins on the acute take. J N Townend Queen Elizabeth Hospital Birmingham
Chest pain and troponins on the acute take J N Townend Queen Elizabeth Hospital Birmingham 3 rd Universal Definition of Myocardial Infarction Type 1: Spontaneous MI related to atherosclerotic plaque rupture
More informationPREVENTIVE AND REHABILITATIVE MANAGEMENT OF ACUTE CORONARY SYNDROMES (NSTEMI, STEMI, PCI)
PREVENTIVE AND REHABILITATIVE MANAGEMENT OF ACUTE CORONARY SYNDROMES (NSTEMI, STEMI, PCI) Dato Dr. Balachandran Kandasamy Institut Jantung Negara 12 th November 2016 KEY MESSAGES 1. Initiate a long-term
More informationPost Operative Troponin Leak: David Smyth Christchurch New Zealand
Post Operative Troponin Leak: Does It Really Matter? David Smyth Christchurch New Zealand Life Was Simple Once Transmural Infarction Subendocardial Infarction But the Blood Tests Were n t Perfect Creatine
More informationTo provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.
ACETYL SALICYLIC ACID TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.
More informationLecture 8 Cardiovascular Health Lecture 8 1. Introduction 2. Cardiovascular Health 3. Stroke 4. Contributing Factors
Lecture 8 Cardiovascular Health 1 Lecture 8 1. Introduction 2. Cardiovascular Health 3. Stroke 4. Contributing Factors 1 Human Health: What s Killing Us? Health in America Health is the U.S Average life
More informationThe Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease
Interventional Cardiology and Cath Labs The Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease Manesh R. Patel MD Chief,
More informationBranko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center
Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center THE END! CHANGABLE Blood pressure Diabetes Mellitus Hyperlipidemia Atrial fibrillation Nicotine Drug abuse Life style NOT CHANGABLE
More informationKey causes of preventable deaths in New Zealand In a population of 10,000 New Zealanders, every year there will be about:
Preventive care - Chronic Disease Management in primary care: a population perspective Rod Jackson University of Auckland New Zealand (22/11/8) Key causes of preventable deaths in New Zealand In a population
More informationWHO-EM/TFI/188/E. Smoking and Cardiovascular health
WHO-EM/TFI/188/E Smoking and Cardiovascular health Smoking and Cardiovascular health MESSAGES TO THE PUBLIC, WOMEN, YOUTH AND CARDIOLOGISTS KEY FACTS Tobacco use has been identified by the World Health
More informationOUTCOME OF THROMBOLYTIC AND NON- THROMBOLYTIC THERAPY IN ACUTE MYOCARDIAL INFARCTION
OUTCOME OF THROMBOLYTIC AND NON- THROMBOLYTIC THERAPY IN ACUTE MYOCARDIAL INFARCTION FEROZ MEMON*, LIAQUAT CHEEMA**, NAND LAL RATHI***, RAJ KUMAR***, NAZIR AHMED MEMON**** OBJECTIVE: To compare morbidity,
More informationLIST OF ABBREVIATIONS
Diabetes & Endocrinology 2005 Royal College of Physicians of Edinburgh Diabetes and lipids 1 G Marshall, 2 M Fisher 1 Research Fellow, Department of Cardiology, Glasgow Royal Infirmary, Glasgow, Scotland,
More informationLa prevenzione secondaria dopo sindrome coronarica acuta. Aldo Pietro Maggioni Centro Studi ANMCO Firenze
La prevenzione secondaria dopo sindrome coronarica acuta Aldo Pietro Maggioni Centro Studi ANMCO Firenze Trial and community-based assessments of in-hospital (A) and 30-day (B) mortality relative to age
More informationSmoking. know the facts
Smoking know the facts DID YOU KNOW? In Northern Ireland, 2,300 people die each year from smoking-related illness more than six people per day. Why stop? Smoking is the main cause of illness and early
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationVALUE OF ACEI IN THE MANAGEMENT OF HYPERTENSION
VALUE OF ACEI IN THE MANAGEMENT OF HYPERTENSION Dr Catherine BESEME Paris 6 th December 2005 6 th International Congress of Bangladesh Society of Medicine Hypertension is a risk factor at the source, with
More informationCardiac Rehabilitation after Primary Coronary Intervention CONTRA
DEBATE SESSION Is there a role for cardiac rehabilitation in the modern era of Percutaneous coronary intervention and coronary artery bypass grafting? Cardiac Rehabilitation after Primary Coronary Intervention
More informationIs Lower Better for LDL or is there a Sweet Spot
Is Lower Better for LDL or is there a Sweet Spot ALAN S BROWN MD, FACC FNLA FAHA FASPC DIRECTOR, DIVISION OF CARDIOLOGY ADVOCATE LUTHERAN GENERAL HOSPITAL, PARK RIDGE, ILLINOIS DIRECTOR OF CARDIOLOGY,
More informationLOW DOSE ASPIRIN CARDIOVASCULAR DISEASE FOR PROPHYLAXIS OF FOR BACKGROUND USE ONLY NOT TO BE USED IN DETAILING
LOW DOSE ASPIRIN FOR PROPHYLAXIS OF CARDIOVASCULAR DISEASE FOR BACKGROUND USE ONLY NOT TO BE USED IN DETAILING Use of Low Dose Aspirin to Treat and Prevent Cardiovascular Disease In recent decades, aspirin
More informationManagement of Stable Ischemic Heart Disease. Vinay Madan MD February 10, 2018
Management of Stable Ischemic Heart Disease Vinay Madan MD February 10, 2018 1 Disclosure No financial disclosure. 2 Overview of SIHD Diagnosis Outline of talk Functional vs. Anatomic assessment Management
More informationClopidogrel has been evaluated in clinical trials that included cardiovascular patients
REVIEW ARTICLE Comparative Benefits of Clopidogrel and Aspirin in High-Risk Patient Populations Lessons From the CAPRIE and CURE Studies Jack Hirsh, CM, MD, FRCPC, FRACP, FRSC, DSc; Deepak L. Bhatt, MD,
More informationQuality Measures MIPS CV Specific
Quality Measures MIPS CV Specific MEASURE NAME Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy CAHPS for MIPS Clinician/Group Survey Cardiac Rehabilitation Patient Referral from
More informationAntiplatelet agents treatment
Session III Comprehensive management of diabetic patients Antiplatelet agents treatment Chonnam National University Hospital Department of Internal Medicine Dong-Hyeok Cho CONTENTS Introduction Prothrombotic
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationGuidelines on cardiovascular risk assessment and management
European Heart Journal Supplements (2005) 7 (Supplement L), L5 L10 doi:10.1093/eurheartj/sui079 Guidelines on cardiovascular risk assessment and management David A. Wood 1,2 * 1 Cardiovascular Medicine
More informationPeripheral Arterial Occlusive Disease- The Challenge in patients with diabetes
Peripheral Arterial Occlusive Disease- The Challenge in patients with diabetes Ashok Handa Reader in Surgery and Consultant Surgeon Nuffield Department of Surgery University of Oxford Introduction Vascular
More informationCindy L. Grines MD FACC FSCAI
Cindy L. Grines MD FACC FSCAI Hofstra Northwell School of Medicine Chair, Cardiology Academic Chief of Cardiology, Northwell Health North Shore University Hospital, Manhasset NY Multivessel Disease in
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationPractical advice on smoking cessation: Patients with long-term conditions
Practical advice on smoking cessation: Patients with long-term conditions Tracy Kirk Primary Care Based Respiratory Nurse Consultant This symposium is organised and funded by Pfizer Prescribing Information
More informationTreatment to reduce cardiovascular risk: multifactorial management
Treatment to reduce cardiovascular risk: multifactorial management Matteo Anselmino, MD PhD Assistant Professor San Giovanni Battista Hospital Division of Cardiology, Department of Internal Medicine University
More informationPatient characteristics Intervention Comparison Length of followup
ISCHAEMIA TESTING CHAPTER TESTING FOR MYCOCARDIAL ISCHAEMIA VERSUS NOT TESTING FOR MYOCARDIAL ISCHAEMIA Ref ID: 4154 Reference Wienbergen H, Kai GA, Schiele R et al. Actual clinical practice exercise ing
More informationCardiovascular disease and varenicline (Champix)
Cardiovascular disease and varenicline (Champix) 2012 National Centre for Smoking Cessation and Training (NCSCT). Version 2: June 2012. Authors: Leonie S. Brose, Eleni Vangeli, Robert West and Andy McEwen
More informationCardiovascular disease and varenicline (Champix)
Cardiovascular disease and varenicline (Champix) 2013 National Centre for Smoking Cessation and Training (NCSCT). Version 3: August 2013. Authors: Leonie S. Brose, Eleni Vangeli, Robert West and Andy McEwen
More informationSMOKING CESSATION IS HARD
POWER TO BREAK THE HOLD OF NICOTINE ADDICTION 1 SMOKING CESSATION IS HARD Most smokers try to quit 5-7 times before they are successful. 2 Why is it so hard to quit? Typical withdrawal symptoms from stopping
More informationDR ALEXIA STAVRATI CARDIOLOGIST, DIRECTOR OF CARDIOLOGY DEPT, "G. PAPANIKOLAOU" GH, THESSALONIKI
The Impact of AF on Natural History of CAD DR ALEXIA STAVRATI CARDIOLOGIST, DIRECTOR OF CARDIOLOGY DEPT, "G. PAPANIKOLAOU" GH, THESSALONIKI CAD MOST COMMON CARDIOVASCULAR DISEASE MOST COMMON CAUSE OF DEATH
More informationPreventing ill health -
Preventing ill health - tobacco and alcohol screening Striving for excellence Screening When you attended hospital for assessment and treatment you may also receive routine tobacco and alcohol screening
More informationThe Beneficial Role of Angiotensin- Converting Enzyme Inhibitor in Acute Myocardial Infarction
The Beneficial Role of Angiotensin- Converting Enzyme Inhibitor in Acute Myocardial Infarction Cardiovascular Center, Korea University Guro Hospital 2007. 4. 20 Seung-Woon Rha, MD, PhD Introduction 1.
More informationIs it ever too late for cardiovascular prevention and rehabilitation? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany
Is it ever too late for cardiovascular prevention and rehabilitation? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany The demographic issue Life expectancy is increasing Patients are getting
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationDiabetes and the Heart
Diabetes and the Heart Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 6, 2012 Outline Screening for diabetes in patients with CAD Screening for CAD in patients with
More informationJanet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode Island Cardiology Center
Primary and Secondary Prevention of Coronary Artery Disease: What is the role of non statin drugs (fenofibrates, fish oil, niacin, folate and vitamins)? Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode
More informationAssociate Professor Gerry Devlin
Associate Professor Gerry Devlin Clinical Cardiologist and Interventional Cardiologist NZ Heart Foundation Hamilton 9:00-9:15 Secondary Prevention of IHD The Challenge of Secondary Prevention Associate
More informationWhat can the NHS do to reduce premature mortality? Professor Sir Mike Richards NHS Health Check National Learning Event April 2013
What can the NHS do to reduce premature mortality? Professor Sir Mike Richards NHS Health Check National Learning Event April 2013 The role of the NHS in reducing premature mortality Overview The scale
More informationThe Clinical Case for Smoking Cessation for CARDIOVASCULAR PATIENTS
The Clinical Case for Smoking Cessation for CARDIOVASCULAR PATIENTS What is this initiative aiming to achieve? The aim of this initiative is to provide clinical support for temporary abstinence with a
More informationDr Joan Leighton. Professor Gerry Devlin. 14:00-14:55 WS #106: Whats Topical in Cardiology 15:05-16:00 WS #116: Whats Topical in Cardiology (Repeated)
Professor Gerry Devlin Clinical Cardiologist and Interventional Cardiologist NZ Heart Foundation Hamilton Dr Joan Leighton General Practitioner Heart Foundation Christchurch 14:00-14:55 WS #106: Whats
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationMacrovascular Disease in Diabetes
Macrovascular Disease in Diabetes William R. Hiatt, MD Professor of Medicine/Cardiology University of Colorado School of Medicine President, CPC Clinical Research Conflicts CPC Clinical Research (University-based
More informationCARING FOR A LOVED ONE AFTER A HEART ATTACK OR STROKE
CARING FOR A LOVED ONE AFTER A HEART ATTACK OR STROKE AFTER YOUR LOVED ONE HAS HAD A HEART ATTACK OR STROKE Heart attack and stroke affects the whole family. If your loved one has had a heart attack or
More information